These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30073393)

  • 1. Glucocorticoids in multiple myeloma: past, present, and future.
    Burwick N; Sharma S
    Ann Hematol; 2019 Jan; 98(1):19-28. PubMed ID: 30073393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Glucocorticoids and multiple myeloma. Mechanism of action, resistance and clinical use].
    Paule B; Clerc D; Brion N
    Ann Med Interne (Paris); 1998 Dec; 149(8):502-7. PubMed ID: 10021903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of glucocorticoids in the treatment of multiple myeloma].
    Juge-Morineau N; Harousseau JL; Bataille R
    Ann Med Interne (Paris); 1996; 147(8):576-9. PubMed ID: 9137685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclic adenosine-3',5'-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma.
    Krett NL; Zell JL; Halgren RG; Pillay S; Traynor AE; Rosen ST
    Clin Cancer Res; 1997 Oct; 3(10):1781-7. PubMed ID: 9815564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.
    Neri P; Yasui H; Hideshima T; Tassone P; Raje N; Catley LP; Ishitsuka K; Blotta S; Kiziltepe T; Ocio EM; Fulciniti M; Kanekal S; Elliott GT; Munshi NC; Anderson KC
    Br J Haematol; 2006 Jul; 134(1):37-44. PubMed ID: 16803565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma.
    Kervoëlen C; Ménoret E; Gomez-Bougie P; Bataille R; Godon C; Marionneau-Lambot S; Moreau P; Pellat-Deceunynck C; Amiot M
    Oncotarget; 2015 Sep; 6(29):26922-34. PubMed ID: 26323097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma.
    Thomas AL; Coarfa C; Qian J; Wilkerson JJ; Rajapakshe K; Krett NL; Gunaratne PH; Rosen ST
    Nucl Recept Signal; 2015; 13():e006. PubMed ID: 26715915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-6-independent expression of glucocorticoid receptor is upregulated by triptolide in multiple myeloma.
    Yang M; Shen JK; Huang J; Du HP; Ma QL; Jin J
    Leuk Lymphoma; 2009 May; 50(5):802-8. PubMed ID: 19330649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
    Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E
    Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
    Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; San Miguel JF; Cavenagh JD; Anderson KC
    Br J Haematol; 2007 Jun; 137(5):429-35. PubMed ID: 17451408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma.
    Deshantri AK; Fens MH; Ruiter RWJ; Metselaar JM; Storm G; van Bloois L; Varela-Moreira A; Mandhane SN; Mutis T; Martens ACM; Groen RWJ; Schiffelers RM
    J Control Release; 2019 Feb; 296():232-240. PubMed ID: 30682443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapsed and refractory multiple myeloma: new therapeutic strategies.
    Gentili S; Lonial S
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):861-90. PubMed ID: 25212887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience.
    Soyer N; Patır P; Uysal A; Duran M; Ünal HD; Durusoy R; Tombuloğlu M; Şahin F; Töbü M; Vural F; Saydam G
    Turk J Med Sci; 2018 Aug; 48(4):777-785. PubMed ID: 30119153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
    Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.
    Bahlis NJ; McCafferty-Grad J; Jordan-McMurry I; Neil J; Reis I; Kharfan-Dabaja M; Eckman J; Goodman M; Fernandez HF; Boise LH; Lee KP
    Clin Cancer Res; 2002 Dec; 8(12):3658-68. PubMed ID: 12473574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
    Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.
    Benson DM; Cohen AD; Jagannath S; Munshi NC; Spitzer G; Hofmeister CC; Efebera YA; Andre P; Zerbib R; Caligiuri MA
    Clin Cancer Res; 2015 Sep; 21(18):4055-61. PubMed ID: 25999435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
    Shah JJ; Kaufman JL; Zonder JA; Cohen AD; Bensinger WI; Hilder BW; Rush SA; Walker DH; Tunquist BJ; Litwiler KS; Ptaszynski M; Orlowski RZ; Lonial S
    Cancer; 2017 Dec; 123(23):4617-4630. PubMed ID: 28817190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.